BIOTIE THERAPIES CORP. Stock Exchange Release 3 April 2014 at 2.45 pm Biotie: Change in the number of votes Biotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares held as treasury shares, that were issued on 2 January 2014, pursuant to the Stock Option Plan 2011 and the Equity Incentive Plan 2011 as follows: Shares conveyed Cumulative shares conveyed since Remaining shares to be conveyed 2 January 2014 752,500 1,091,250 2,230,410 Under the Stock Option Plan 2011, the owners of the stock options may subscribe for a maximum total of 7,401,000 new shares in the Company or existing shares held by the Company. A total of 427,500 shares have been subscribed for during the period 28 February 2014 and 3 April 2014 and 427,500 of the treasury shares will be used for these share subscriptions. The subscription price of EUR 0.01 per share has been fully paid by the employee and the EUR 4,275 funds received will be credited to the Company's reserve for non-restricted equity. The first vesting period of the Equity Incentive Plan 2011 ended on 5 January 2014, after which the Company's shares shall be delivered to employees on the basis of the granted share units. It was resolved pursuant to the authorization of the Annual General Meeting of the Shareholders to issue 325,000 existing treasury shares to the employees without consideration for the purposes of remunerating the employees pursuant to the terms and conditions of the Equity Incentive Plan 2011 and thus, there is an especially weighty financial reason to derogate from the pre-emptive right of the shareholders, as referred to in Chapter 9 Section 4(1) of the Companies Act (624/2006, as amended). The conveyed shares previously held as treasury shares have not carried any voting rights. The conveyance does not affect the number of registered shares. After the conveyances the changes are as follows: Increase in number of Total amount of Number of the Total number outstanding shares voting rights Company's shares held of registered by the Group shares 752,500 447,305,198 8,727,200 456,032,398 Turku, 3 April 2014 Biotie Therapies Corp. Timo Veromaa, President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com www.biotie.com DISTRIBUTION: NASDAQ OMX Helsinki Ltd Main Media [HUG#1774201]